The Van den Eynde group at the Oxford Ludwig Institute for Cancer Research, is seeking an experienced Senior Postdoctoral Scientist to join the research programme developing new cancer vaccines based on a recombinant virus platform and combination therapies for effective cancer treatment.
You will participate in the Ludwig funded research programme led by Prof Benoit Van den Eynde, to understand the interplay between tumours and the immune system and to develop next-generation cancer vaccines. You will be responsible for training junior staff in cellular immunology and in vivo work, and you will supervise junior staff in the professor’s absence. You will operate laboratory equipment used for all aspects of cell/molecular biology/biochemistry, and be responsible for good laboratory practice, including the use of electronic lab notebooks. In addition, you will assist in dissemination of findings of the research group by authorship of manuscripts, presentation of results at meetings, and contribution to the group website.
It is essential that you hold a PhD/DPhil in Molecular Biology/Immunology or other related subject, and have relevant postdoctoral experience. You will have experience with immunology and standard recombinant DNA, and you will also be experienced in immunology techniques, including flow cytometry for the evaluation of T cell responses to antigens. Additionally, experience in tumour immunology and experience with in vivo handling are essential. You will have a strong and active publication record and familiarity with the existing literature and research in the field.
Applications for this vacancy are to be made online and you will be required to upload a supporting statement and CV as part of your online application. Your supporting statement must explain how you meet each of the selection criteria for the post using examples of your skills and experience.
This position is offered full time on a fixed term contract for 3 years and is funded by Ludwig. Only applications received before 12 midday on 22 April 2024 will be considered. Please quote 171902 on all correspondence.